Bio-Thera, a Guangzhou clinical-stage biopharma, filed a China IND for its anti-Trop2 antibody drug conjugate, BAT8003. Bio-Thera intends to test the ADC as a treatment for Trop2-positive cancers, including triple-negative breast cancer and gastric cancer. Bio-Thera is developing a pipeline of innovative therapies, including immunotherapies, along with biosimilars for China use. At the moment, the company has three biosimilars and one ADC in late-stage trials, plus four candidates in early clinical-stage development.
Source: China Biotoday
